Table 1.
Demographics and clinical characteristics of 263 Omicron variant-infected hospitalized patients complicated with myocardial injury in the ICU group and non-ICU group.
| Patients, n (%) | ||||
|---|---|---|---|---|
| Characteristic | Total (n = 263) | ICU group (n = 53) | Non-ICU group (n = 210) | p-value |
| Demographics | ||||
| Age, median (range), years | 87 (61–104) | 88 (66–98) | 87 (61–104) | 0.42 |
| Female | 155 (58.94%) | 39 (73.58%) | 116 (55.24%) | 0.015 |
| Previous madical history | ||||
| Hypertension | 184 (69.96%) | 38 (71.70%) | 146 (69.52%) | 0.758 |
| Coronary artery disease | 117 (44.49%) | 22 (41.51%) | 95 (45.24%) | 0.625 |
| Cerebrovascular disease | 92 (34.98%) | 26 (49.06%) | 66 (31.43%) | 0.016 |
| Diabetes | 57 (21.67%) | 12 (22.64%) | 45 (21.43%) | 0.848 |
| Arrhythmia | 47 (17.87%) | 9 (16.98%) | 38 (18.10%) | 0.850 |
| Neoplasm | 21 (7.98%) | 4 (7.55%) | 17 (8.10%) | 1.000 |
| Chronic kidney disease | 34 (12.93%) | 11 (20.75%) | 23 (10.95%) | 0.057 |
| Chronic pulmonary disease | 6 (2.28%) | 1 (1.89%) | 5 (2.38%) | 1.000 |
| Heart failure | 12 (4.56%) | 2 (3.77%) | 10 (4.76%) | 1.000 |
| Vaccination | ||||
| Unvaccinated/Partially (0/1 dose) | 206 (78.33%) | 41 (77.36%) | 165 (78.57%) | 0.848 |
| Fully vaccinated/Booster doses (2/3 doses) | 11 (1.42%) | 2 (0.76%) | 9 (1.77%) | 1.000 |
| Unknown | 46 (8.55%) | 10 (5.70%) | 36 (10.02%) | 0.768 |
| Clinical laboratory biomarkers, median (IQR)/mean ( ± SD) | ||||
| Ct-ORF1ab | 20.22 (17.8–23.63) | 20.11 (18.61–23.94) | 20.23 (17.79–23.69) | 0.594 |
| Ct-N | 20.65 (18.3–24.15) | 20.65 (18.75–24.63) | 20.65 (18.21–24.01) | 0.511 |
| WBC, 109/L | 5.41 (4.18–7.08) | 7.94 (5.42–11.39) | 5.13 (4.01–6.66) | <0.001 |
| NEUT, 109/L | 3.63 (2.44–5.68) | 6.23 (3.80–8.97) | 3.25 (2.27–4.59) | <0.001 |
| NEUT, % | 68.22 ± 14.51 | 78.02 ± 13.02 | 65.74 ± 18.83 | <0.001 |
| LYM, 109/L | 1.05 (0.73–1.45) | 1.05 (0.60–1.39) | 1.05 (0.75–1.46) | 0.319 |
| LYM, % | 19.65 (11.8–30.28) | 11.50 (8.15–19.80) | 21.60 (13.90–31.65) | <0.001 |
| Hemoglobin, g/L | 117.43 ± 21.40 | 112.42 ± 22.91 | 118.70 ± 20.86 | 0.056 |
| D-dimer, mg/L | 1.05 (0.63–2.04) | 1.78 (1.07–4.21) | 0.90 (0.56–1.79) | <0.001 |
| Interleukin-6, pg/mL | 44.60 (25.90–149.18) | 69.30 (27.94–164.05) | 43.65 (24.70–137.33) | 0.113 |
| Procalcitonin, ng/mL | 0.075 (0.023–0.229) | 0.241 (0.097–0.947) | 0.06 (0.02–0.13) | <0.001 |
| CRP, mg/L | 21.45 (7.11–63.99) | 72.03 (12.97–146.63) | 16.42 (5.55–50.24) | <0.001 |
| SAA, mg/L | 74.81 (23.88–305.76) | 288.22 (49.87–320.00) | 58.40 (19.99–219.29) | <0.001 |
| Myoglobin, ng/L | 96.24 (66.70–229.48) | 161.80 (82.99–567.65) | 92.24 (63.77–166.70) | <0.001 |
| CK-MB, ng/L | 3.01 (1.83–4.86) | 4.27 (2.34–7.43) | 2.77 (1.77–4.22) | <0.001 |
| NT-proBNP, pg/mL | 1,022.00 (413.58–2,504.00) | 2,054.00 (890.40–5,621.00) | 892.40 (353.60–2,134.00) | <0.001 |
| TP, g/L | 59.49 ± 5.95 | 59.77 ± 5.88 | 58.39 ± 6.20 | 0.145 |
| AST, U/L | 16.42 (10.79–24.37) | 16.83 (10.66–24.63) | 16.14 (10.78–24.48) | 0.775 |
| ALT, U/L | 27.81 (21.20–40.29) | 33.66 (21.53–49.65) | 26.62 (21.20–37.65) | 0.047 |
| eGFR | 80.00 (47.50–107.00) | 61.00 (34.00–97.00) | 83.00 (55.00–107.50) | 0.012 |
| BUN, mmol/L | 8.12 (5.80–11.98) | 10.64 (7.32–16.13) | 7.64 (5.59–10.76) | <0.001 |
| sCr, μmol/L | 75.20 (55.80–106.45) | 87.80 (61.30–161.20) | 72.65 (55.63–100.80) | 0.041 |
| Therapy | ||||
| Antivirus(plaxlovid) | 238 (90.49%) | 52 (98.11%) | 186 (88.57%) | 0.035 |
| Heparin | 213 (80.99%) | 48 (90.57%) | 165 (78.57%) | 0.051 |
| Glucocorticoids | 67 (25.48%) | 39 (73.58%) | 28 (13.33%) | <0.001 |
| Transnasal high flow oxygen therapy | 19 (7.22%) | 12 (22.64%) | 7 (3.33%) | <0.001 |
| Non-invasive ventilation | 48 (18.25%) | 35 (66.04%) | 13 (6.19%) | <0.001 |
| Invasive mechanical ventilation | 20 (7.60%) | 19 (35.85%) | 1 (0.48%) | <0.001 |
Values were presented as mean ± SD for continuous variables with a normal distribution, or median (IQR) for continuous variables without a normal distribution.
Ct-ORF1ab, Cycle Threshold-ORF1ab gene; Ct-N, Cycle Threshold-N gene; WBC, white blood cell; NEUT, neutrophil; LYM, lymphocytes; CRP, C-reactive protein; SAA, serum amyloid A; CK-MB, creatinine kinase-myocardial band; NT-proBNP, N-terminal pro-B-type natriuretic peptide; TP, total protein; LDH, lactate dehydrogenase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, glomerular filtration rate (estimated); BUN, blood urea nitrogen; sCr, serum creatinine.
The cutoffs for laboratory examinations: WBC: 3.5–9.5 × 109/L; Neut: 1.8–6.3 × 109/L; Neut%: 40%–75%; LYM: 1.1–3.2 × 109/L; LYM%: 20%–50%; hemoglobin: 120–150 g/L; D-Dimer ≤ 0.5 mg/L; Interleukin-6 ≤ 6.6 pg/mL; Procalcitonin < 0.5 ng/mL; CRP: 0–6 mg/L; SAA: 0–10 mg/L; Myoglobin: male: 26.56–72.48 ng/L, female: 24.24–57.57 ng/L; CK-MB: male: ≤4.88 ng/L, female: ≤3.63 ng/L; NT-proBNP < 900 pg/mL; Tp: 65–85 g/L; Potassium: 3.5–5.3 mmol/L; Sodium: 137–147 mmol/L; Chlorate: 99–110 mmol/L; LDH: 120–250 U/L; ALT: male:9–50 U/L, female: 7–40 U/L; AST: male: 15–40 U/L, female: 13–35 U/L; eGFR: 90–120; BUN: male: 3.6–9.5 mmol/L, female: 3.1–8.8 mmol/L; sCr: male: 57–111 μmol/L, female: 41–81 μmol/L.